An American remedy for 'post -trauma -disorder' of MDMA, which faces the rejection of experts

A consultative committee that includes US experts on Tuesday decided to refuse to license a drug for post -trauma deviation in the United States, based on MDMA, a drug also known as ‘Esstasi’, and is being consumed illegally on some occasions. Lykos Therapeutics produces this medicine, which is given to patients parallel to psychotherapy sessions, and clinical experiments were performed, but experts concluded the insufficient procedures used to perform these experiments and the strength of the results. The Food and Drug Administration “FDA”, the Committee of Independent Experts, has asked that the opinion on this data is healing, and although the government is not bound by what this committee finds, it is rare not to take its opinion. During the vote, nine of the 11 experts saw that the drug did not prove its effectiveness in the treatment of post -traumatic disorder, and ten out of the 11 believe that its benefits do not exceed the risks. “I think it’s an enthusiastic remedy … and I acknowledged that we need new and better drugs for post -shock disorder,” Paul Holtzheimers of the American National Center for PTSD said, and he expressed his belief that “it allows), if it is effective, or in terms of safety”. After a shocking event, a shocking event occurs before shock disorder and post -traumatic disorder, and about 5% of Americans suffer, and those dealing with it are more vulnerable to the risk of suicidal behavior and drug addiction, and there are only two medicines accredited in the United States, but they do not always enjoy effectiveness. About 200 people participated in two similar clinical trials in which half of the participants received the medicine “MDMA” (or midomavitamin), and the other half was a false medicine during three sessions, each eight hours, separated by weeks and was performed in the presence of a psychotherapist. The scientific director of the company “Likos Thirapotics” Beira Yazar Closnsky said the experiment was conducted in a “comfortable room with a bank”, with “soft lighting”, and a number of psychotherapy sessions were separated between the doses. The Food and Drug Administration noted that the participants who received MMA had a quick and great improvement at the clinical and sustainable level appeared to be in the symptoms of stress in their shock, “but the government believes that” factors make it difficult to explain this data. ” On the one hand, the patients were largely capable of the strong effects of the MDMA means on the mood and sensation, to distinguish between whether they received the actual or imaginary medicine, a factor that may have affected the results. On the other hand, ‘FDA’ criticized which it described as ‘incomplete’ orthodontics of the potential side effects, especially with regard to the dangers of the drug on the heart, and the participants noticed a significant increase in blood pressure and the pace of the pulse rate. The committee experts also pointed out that a high percentage of patients covered by the clinical experiment previously treated the “MDMA” darcotics in the past, and they warned that it could possibly distort the results of the experiment. The potential conditions for the use of the middle and the experience of the experiment also influenced by what was included in a recent report by Irish, which reviewed clinical trials, and said that the participants in these experiments are encouraging to report the benefits of the drug, not its side effects. “We take these allegations seriously, and they made us a little worried.” In a statement, Likos Therapotix expected in a statement that the food and drug administration would make a decision on the license to use before mid-August. If the commission allows this medicine, it is expected to be used in a strict way, and that it will limit it to some accredited institutions, provided the patients are included in records that enable the follow -up of their status. These are also the conditions for the sessions that supervise by two people, and patients can only return home with another adult person, and they may not drive their cars the next day. MDMA is currently legally prohibited in the United States, and the license will be formed for medical treatment. Scientists have looked very seriously at the possibility of using narcotic substances in general, for example, to treat different diseases and mental disorders, including depression.